SCHEMBL27625945

SCHEMBL27625945

COC(=O)n1c(=O)cc(C)[nH]c1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 6/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
KDM4E B2RXH2 4/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
TYMP P19971 3/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ENPP3 O14638 1/20 0.33
ALPL P05186 1/20 0.33
XIAP P98170 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27402173 0.79 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1MAPTGAAHTT
SCHEMBL12368670 0.79 ALOX15 (0.41) SMN1; SMN2ALDH1A1LMNAKDM4EHPGD
SCHEMBL27625946 0.75 TYMP (0.55) TYMPMEN1KMT2ACYP1A2
SCHEMBL29860930 0.72 CYP1A2 (0.38) ALDH1A1MAPTGAAHTTKDM4E
SCHEMBL4767741 0.69 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1MAPTLMNAGAA
SCHEMBL2632820 0.66 YTHDF2 (0.52) SMN1; SMN2ALDH1A1LMNAGAAHTT
SCHEMBL10296643 0.66 DAO (0.51) MEN1KMT2ACYP1A2
SCHEMBL24420566 0.65 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MAPTLMNAGAA
SCHEMBL27816351 0.65 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1MAPTLMNAGAA
SCHEMBL4618373 0.64 KDM4E (0.46) SMN1; SMN2ALDH1A1MAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103003294-A Gene fusion targeted therapy UNIV MICHIGAN 2013-03-27 CN disclosed
CN-101223269-B Compositions and methods for treating tissue CONJUGON INC 2013-03-27 CN disclosed
CN-101341256-B Recurrent gene fusions in prostate cancer UNIV MICHIGAN 2013-01-23 CN disclosed
CN-101014608-B Methods and compositions for inhibiting gene expression PRONAI THERAPEUTICS INC 2011-07-06 CN disclosed
CN-101583624-A Compositions and methods for diagnosing and treating cancer ONCOMED PHARM INC (US) 2009-11-18 CN disclosed
CN-101460634-A Methods and compositions for targeting C-REL CORNELL RES FOUNDATION INC (US) 2009-06-17 CN disclosed
CN-101389758-A Methods and compositions for modulating apoptotic pathways UNIV NEW YORK (US) 2009-03-18 CN disclosed
CN-101381725-A Circular dumbbell decoy oligodeoxynucleotide (CDODN) containing transcription DNA binding sites ANGES MG INC (JP) 2009-03-11 CN disclosed
CN-101341256-A Recurrent gene fusions in prostate cancer UNIV MICHIGAN (US) 2009-01-07 CN disclosed
CN-101223269-A Compositions and methods for treating tissue CONJUGON INC (US) 2008-07-16 CN disclosed
CN-1934255-A Combination therapy for the treatment of ocular neovascular diseases OSI EYETECH INC (US) 2007-03-21 CN disclosed
CN-1910291-A Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway UNIV MICHIGAN (US) 2007-02-07 CN disclosed
CN-1852974-A Compositions and methods for treating and diagnosing cancer UNIV MICHIGAN (US) 2006-10-25 CN disclosed
CN-1688714-A Diagnosis and treatment of the tuberous sclerosis pathway UNIV MICHIGAN (US) 2005-10-26 CN disclosed
CN-1665929-A Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing transcription DNA binding sites ANGES MG INC (JP) 2005-09-07 CN disclosed